PapersPMID:35352233
The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials.
- findings
- 3
- compound
- 1
- endpoints
- 3
berberine- Study, every finding
- meta-analysis
- Dose studied, every finding
- berberine 0.09 g to 1.8 g daily across trials
- Population, every finding
- Chinese patients with metabolic syndrome and related disorders (diabetes, diabetic nephropathy, cardiovascular disease, polycystic ovary syndrome and others) in pooled RCTs; berberine mostly added to background drug therapy that the control arm also received, with placebo, no treatment or another drug as comparator
What moved
How to read these marks →“The pooled findings using random-effects model showed that berberine use in patients with MetS and related disorders significantly decreased the concentration level of CRP (SMD = − 1.54; 95% CI − 1.86, − 1.22; p < 0.05), TNF-α (SMD = − 1.02; 95% CI − 1.27, − 0.77; p < 0.05), and IL-6 (SMD = − 1.17; 95% CI − 1.53, − 0.81; p < 0.05).”
- Decreases C-reactive protein concentration
moderatereplicated ×3
- Effect
- −1.54 standardised mean difference, 95% CI −1.86 to −1.22
- Effect
- −1.02 standardised mean difference, 95% CI −1.27 to −0.77
- Effect
- −1.17 standardised mean difference, 95% CI −1.53 to −0.81
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Chinese patients with metabolic syndrome and related disorders (T2DM, obesity, CVD, PCOS, diabetic nephropathy, etc.), 52 RCTs, 4616 patients
- Participants
- 4,616
- Comparator
- no treatment / placebo
- Duration
- not reported
- Endpoints measured
- 46